"uuid:ID","versionIdentifier","id","instanceType","rationale"
"9fd73329-2a06-4f04-ab91-22a019f3d562","2","StudyVersion_1","StudyVersion","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
